查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017818

阿茲海默症診斷血液生物標記市場：市場規模、佔有率和趨勢分析（按類型、技術、最終用途和地區分類），細分市場預測（2026-2033 年）

Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis By Type, By Technology, By End-use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

阿茲海默症診斷血液生物標記市場概述

2025 年，用於診斷阿茲海默症的血液生物標記的全球市場規模估計為 1.6922 億美元，預計到 2033 年將達到 5.299 億美元。

預計2026年至2033年的年複合成長率（CAGR）將達到17.37%。一個關鍵轉折點是美國FDA於2025年5月16日批准了Fujiri Bio公司的「Lumipulse G pTau217/BETA-澱粉樣蛋白1-42血漿比值」核准。這是首個核准用於輔助診斷阿茲海默症的血液檢測，隨後LabCorp於2025年8月18日在全美範圍內迅速推出了該檢測。

這些進展有望降低推廣應用的障礙（例如，更清晰的法規和更完善的分銷管道），加快保險公司採用和臨床醫生提出檢測需求，並進一步提升血液檢測相對於影像學和腦脊髓液 (CSF) 檢測的成長速度。根據在 2025 年美國免疫學大會 (AAIC 2025) 上提出的指南以及阿茲海默症協會發布的指南，靈敏度達到 90% 或更高、特異性達到 75-90% 或更高的血液生物標記 (BBM) 可用於對合適的患者進行澱粉樣蛋白 PET 和 CSF 檢測的初步篩選，如果這些性能更高的方法可作為性能更高的患者進行檢測。包含 P-tau217 的檢測組合在檢測澱粉樣蛋白和Tau蛋白病變方面始終優於舊一代檢測方法（例如單獨使用 AB42/40 或 p-tau181）。臨床實務中的產品數據也日趨一致。根據美國神經病學會 (AAN) 會議上發表的一項分析，Quest 公司的 2025 AD-Detect™ 檢測阿茲海默症的敏感性和特異性均超過 90%。同時，臨床總結指出，FDA已通過核准的Lumipulse 檢測的陽性符合率約為 92%，陰性符合率約 97%。隨著臨床醫生對「陽性/陰性」結果的準確性越來越有信心，檢測需求正從專門的記憶診所轉向更廣泛的一線診療，這導致檢測數量增加，並將腦功能監測 (BBM) 確立為首選診斷步驟。

技術成熟和臨床檢驗正在加速這一進程。針對磷酸化Tau（尤其是p-tau217）的血液檢測已獲得突破性醫療器材認定，並已獲得FDA的全面核准，這反映了其高度的臨床有效性和效用。產學研聯盟（例如威斯康辛大學麥迪遜分校、約翰霍普金斯大學和隆德大學）提供了支持核准的體外診斷醫療設備（IVD）的關鍵數據。已發表的綜述得出結論：血液生物標記檢測（BBMT）的價值在於其可降低侵入性並實現早期分診，這對於疾病修正治療在疾病前驅期/輕症階段最為有效至關重要。

市場應用實例包括在參考實驗室實施以及整合到醫院失智症門診的臨床流程中。在這些情況下，p-tau217/AB 比值陽性可加速 PET 掃描的安排。同時，陰性結果可避免昂貴的檢測。隨著平台的擴展，預計將引入更多檢測參數（神經絲輕鏈、GFAP、AB42/40）、反射演算法和組合檢測方案，從而提高靈敏度和特異性，支持縱向監測，並透過定期檢測（而非僅限於一次性診斷）來實現盈利。

目錄

第1章：阿茲海默症診斷血液生物標記市場：分析方法和範圍

第2章：阿茲海默症診斷血液生物標記市場：執行摘要

第3章：阿茲海默症診斷血液生物標記市場：影響因素、趨勢和範圍

  • 市場區隔和範圍
  • 市場歷史及展望
  • 市場動態
  • 市場動態分析
  • 市場限制因素分析
  • 波特五力分析
  • PESTEL 分析
  • 管道分析

第4章：阿茲海默症診斷血液生物標記市場：按類型分類的估計和趨勢分析

  • 阿茲海默症診斷血液生物標記市場：波動分析（按類型分類）
  • 澱粉樣蛋白相關標記物
  • Tau蛋白相關標記
  • 神經退化
  • 其他

第5章：阿茲海默症診斷血液生物標記市場：按技術分類的估計和趨勢分析

  • 阿茲海默症診斷血液生物標記市場：波動分析（按技術分類）
  • 免疫檢測
  • 基於質譜的分析
  • 下一代平台
  • 其他

第6章：阿茲海默症診斷血液生物標記市場：按最終用途分類的估計和趨勢分析

  • 阿茲海默症診斷血液生物標記市場：按最終用途分類的波動分析
  • 臨床檢查室/醫院檢查室
  • 製藥和生物技術
  • 學術研究機構
  • 其他

第7章：阿茲海默症診斷血液生物標記市場：區域業務分析

  • 市場概述：按地區分類
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 西班牙
    • 法國
    • 義大利
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 夥伴關係
    • 企業併購
    • 商業夥伴關係
    • 資金籌措
  • 主要企業市佔率分析（2025 年）
  • 企業熱力圖分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Quanterix
    • Fujirebio
    • C2N Diagnostics
    • Labcorp
    • Quest Diagnostics Incorporated
    • Siemens Healthineers
    • Lilly USA, LLC
    • Abbott
    • ALZpath
Product Code: GVR-4-68040-720-2

Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Summary

The global blood-based biomarker for Alzheimer's disease diagnostics market size was estimated at USD 169.22 million in 2025 and is projected to reach USD 529.90 million by 2033, growing at a CAGR of 17.37% from 2026 to 2033. A pivotal catalyst was the U.S. FDA's May 16, 2025, marketing clearance of Fujirebio's Lumipulse G pTau217/B-amyloid 1-42 plasma ratio-the first Alzheimer's blood test cleared to aid diagnosis-quickly followed by Labcorp's nationwide launch on Aug 18, 2025.

These steps lower adoption friction (regulatory clarity, distribution) and are expected to accelerate payer uptake and clinician ordering, intensifying the growth curve for blood tests relative to imaging and CSF. Guidance presented at AAIC 2025 and published by the Alzheimer's Association states that blood-based biomarker (BBM) tests with >=90% sensitivity and >=75-90% specificity can triage-and at higher performance, substitute for-amyloid PET or CSF testing in appropriate patients. P-tau217-containing panels consistently outperform earlier generations (AB42/40 or p-tau181 alone) for detecting amyloid and tau pathology. Real-world product data are converging: Quest's 2025 AD-Detect(TM) reported >90% sensitivity and specificity for Alzheimer's pathology in AAN-presented analyses, while clinical summaries highlight ~92% positive and ~97% negative agreement for the FDA-cleared Lumipulse test. As clinicians gain confidence in rule-in/rule-out accuracy, ordering shifts from specialty memory clinics to broader frontline settings, expanding test volumes, and normalizing BBMs as the first diagnostic step.

Technology maturation and clinical validation add momentum. Blood assays targeting phosphorylated tau (especially p-tau217) have received Breakthrough Device designations and now full FDA clearance, reflecting strong clinical validity and utility. Academic-industry consortia (e.g., UW-Madison, Johns Hopkins, Lund) supplied pivotal data underpinning the cleared IVD. Published reviews conclude that blood-based biomarker tests (BBMTs) bring value by reducing invasiveness and enabling earlier triage-crucial when disease-modifying therapies are most effective in prodromal/mild stages.

Market traction examples include reference lab launches and hospital adoption of memory-clinic pathways, where a positive p-tau217/AB ratio can expedite PET scheduling. At the same time, a negative result can avoid costly scans. As platforms scale, expect menu expansion (neurofilament light, GFAP, AB42/40), reflex algorithms, and bundled panels, improving sensitivity/specificity and supporting longitudinal monitoring-opening recurring-test revenue beyond one-time diagnosis.

Global Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood-based biomarker for Alzheimer's disease diagnostics market report based on type, technology, end-use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Amyloid-related markers
  • Tau-related markers
  • Neurodegeneration
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassays
  • Mass spectrometry-based assays
  • Next-generation platforms
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical laboratories & hospital labs
  • Pharma & biotech
  • Academic & research institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Technology Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Regulatory approvals and clinical validation
    • 3.4.2. Rising demand for early and non-invasive diagnosis
    • 3.4.3. Integration with disease-modifying therapies (DMTS)
  • 3.5. Market Restraint Analysis
    • 3.5.1. Reimbursement and coverage challenges
    • 3.5.2. Standardization and validation barriers
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Type Movement Analysis
  • 4.2. Amyloid-related markers
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Tau-related markers
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Neurodegeneration
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Others
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Technology Estimates & Trend Analysis

  • 5.1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Technology Movement Analysis
  • 5.2. Immunoassays
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Mass spectrometry-based assays
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Next-generation platforms
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Others
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: End Use Movement Analysis
  • 6.2. Clinical laboratories & hospital labs
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Pharma & biotech
    • 6.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Academic & research institutes
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Product Launch
    • 8.2.2. Partenership
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2025
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. F. Hoffmann-La Roche Ltd
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Quanterix
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Fujirebio
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. C2N Diagnostics
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Labcorp
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Quest Diagnostics Incorporated
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Siemens Healthineers
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Lilly USA, LLC
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Abbott
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. ALZpath
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 5 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 6 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 9 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 10 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 13 U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 15 Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 23 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 25 UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 26 UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 31 France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 32 France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 34 Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 35 Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 37 Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 38 Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 40 Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 43 Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 44 Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 47 Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 53 Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 54 Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 56 China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 59 India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 60 India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 62 Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 63 Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 65 Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 68 South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 69 South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 73 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 76 Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 79 Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 82 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 83 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 91 UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 92 UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global Blood-based biomarker for Alzheimer's disease diagnostics market- Key market driver analysis
  • Fig. 7 Global Blood-based biomarker for Alzheimer's disease diagnostics market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global Blood-based biomarker for Alzheimer's disease diagnostics market - Porter's analysis
  • Fig. 10 Global Blood-based biomarker for Alzheimer's disease diagnostics market - PESTEL analysis
  • Fig. 11 Global Blood-based biomarker for Alzheimer's disease diagnostics market Type outlook key takeaways
  • Fig. 12 Global Blood-based biomarker for Alzheimer's disease diagnostics market: Type movement analysis
  • Fig. 13 Amyloid-related markers market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Tau-related markers market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Neurodegeneration market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Global Blood-based biomarker for Alzheimer's disease diagnostics market technology outlook key takeaways
  • Fig. 18 Global Blood-based biomarker for Alzheimer's disease diagnostics market: technology movement analysis
  • Fig. 19 Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Mass spectrometry-based assays market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Next-generation platforms market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Global Blood-based biomarker for Alzheimer's disease diagnostics market end use outlook key takeaways
  • Fig. 24 Global Blood-based biomarker for Alzheimer's disease diagnostics market: end use movement analysis
  • Fig. 25 Clinical laboratories & hospital labs market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Pharma & biotech market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Academic & research institutes market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics market: Regional movement analysis
  • Fig. 31 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 34 Mexico Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 36 UK Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 38 France Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 39 Spain Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 41 Denmark Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 42 Sweden Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 44 Asia Pacific Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 45 Japan Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 46 China Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 47 India Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 48 South Korea Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 49 Australia Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 50 Thailand Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 51 Latin America Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 52 Brazil Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 53 Argentina Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 54 MEA Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 55 South Africa Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 56 Saudi Arabia Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 57 UAE Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 58 Kuwait Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 59 Strategy framework